Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?

Michelle N Rheault

doi:10.1016/j.kint.2020.07.011

Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?

Kidney Int. 2020 Dec;98(6):1400-1402. doi: 10.1016/j.kint.2020.07.011.

Author

Michelle N Rheault¹

Affiliation

¹ Division of Pediatric Nephrology, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA. Electronic address: [email protected].

PMID: 33276866
DOI: 10.1016/j.kint.2020.07.011

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are prescribed to slow the progression of kidney disease in patients with Alport syndrome. In a recent publication by Yamamura et al. the authors showed an association of ACEi or ARB treatment with delay in ESKD, even for those patients with severe, truncating mutations. Despite these encouraging findings, there remain a number of clinical questions about the use of ACEi and ARBs in Alport syndrome.

Publication types

Comment

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensins
Genetic Association Studies
Humans
Japan
Male
Nephritis, Hereditary* / drug therapy
Nephritis, Hereditary* / genetics
Pharmaceutical Preparations*

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
Pharmaceutical Preparations